Back to top
more

VAXART (VXRT)

(Delayed Data from OTC)

$0.37 USD

0.37
21,803

0.00 (0.03%)

Updated Aug 5, 2025 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

electroCore (ECOR) delivered earnings and revenue surprises of -17.65% and 3.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cronos Group (CRON) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 0% and 13.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.55% and 4.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of -37.50% and 47.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VAXART (VXRT) delivered earnings and revenue surprises of -400% and 90.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does VAXART, INC. (VXRT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sweta Killa headshot

5 Top-Ranked Stocks That Have More Than Doubled Year to Date

by Sweta Killa

Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.

Zacks Equity Research

VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks Equity Research

Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for VAXART, INC. (VXRT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 15.79% and 1,258%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline

by Zacks Equity Research

VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B

by Zacks Equity Research

ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.

Zacks Equity Research

Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.

Zacks Equity Research

Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Brookdale Senior Living (BKD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Brookdale (BKD) delivered earnings and revenue surprises of -10% and 0.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?